

Claudia Cardone

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9337013/claudia-cardone-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38
papers

1,045
citations

18
h-index

32
g-index

73
ext. papers

1,402
ext. citations

4.3
avg, IF

4.11
L-index

#	Paper	IF	Citations
38	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , 2019 , 76, 22-32	14.4	131
37	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017 , 23, 4675-4688	5.6	70
36	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016 , 22, 6345-61	5.6	69
35	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020 , 18, 405	8.5	64
34	Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. <i>Annals of Oncology</i> , 2020 , 31, 30-40	10.3	58
33	RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. <i>Annals of Oncology</i> , 2018 , 29, 1121-1128	10.3	57
32	EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. <i>Gastroenterology</i> , 2017 , 153, 178-190.e10	13.3	51
31	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. <i>Annals of Oncology</i> , 2016 , 27, 1055-1061	10.3	49
30	AXL is an oncotarget in human colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 23281-96	3.3	45
29	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 41	12.8	37
28	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 845-855	6.1	30
27	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018 , 3, e000299	6	24
26	Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. <i>Molecular Oncology</i> , 2019 , 13, 1827-1835	7.9	21
25	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , 2017 , 8, 68305-68316	3.3	20
24	Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 810-820	8.9	19
23	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017 , 2, e000177	6	19
22	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , 2020 , 86, 102023	14.4	19

21	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , 2019 , 11,	6.6	17
20	Genomic Profiling of Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. <i>Cancers</i> , 2019 , 11,	6.6	14
19	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015 , 21, 4153-64	12.9	13
18	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. <i>JAMA Oncology</i> , 2021 , 7, 1529-1535	13.4	13
17	Computed tomography densitometric study of anti-angiogenic effect of regorafenib in colorectal cancer liver metastasis. <i>Future Oncology</i> , 2018 , 14, 2905-2913	3.6	10
16	Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. <i>ESMO Open</i> , 2017 , 2, e000229	6	10
15	Tocilizumab for patients with COVID-19 pneumonia. The TOCOVID-19 prospective phase 2 trial		9
14	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 138, 1-10	7.5	9
13	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016 , 1, e000107	6	8
12	Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. <i>ESMO Open</i> , 2016 , 1, e000086	6	8
11	Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS731-TPS731	2.2	6
10	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 15	12.8	6
9	Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells. <i>Oncotarget</i> , 2017 , 8, 82773-82783	3.3	5
8	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019 , 4, e000519	6	3
7	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3634-TPS3634	2.2	2
6	The Use of Not-Negative Conclusions to Describe Results of Formally Negative Trials Presented at Oncology Meetings. <i>JAMA Oncology</i> , 2020 , 6, 926-927	13.4	2
5	Dual inhibition of TGF β and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. <i>Medical Oncology</i> , 2021 , 38, 24	3.7	2
4	Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 217-224	1	1

3	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS789-TPS789	2.2	1
2	Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time. <i>European Journal of Cancer</i> , 2021 , 150, 203-210	7.5	1
1	Colorectal Cancer: Locoregional Disease. <i>UNIPA Springer Series</i> , 2021 , 605-616	0.1	